Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

Summary

By guiding initial warfarin dose, pharmacogenetic (PGx) algorithms may improve the safety of warfarin initiation. However, once international normalised ratio (INR) response is known, the contribution of PGx to dose refinements is uncertain. This study sought to develop and validate clinical and PGx dosing algorithms for warfarin dose refinement on days 6–11 after therapy initiation. An international sample of 2,022 patients at 13 medical centres on three continents provided clinical, INR, and genetic data at treatment days 6–11 to predict therapeutic warfarin dose. Independent derivation and retrospective validation samples were composed by randomly dividing the population (80%/20%). Prior warfarin doses were weighted by their expected effect on S-warfarin concentrations using an exponential-decay pharmacokinetic model. The INR divided by that “effective” dose constituted a treatment response index. Treatment response index, age, amiodarone, body surface area, warfarin indication, and target INR were associated with dose in the derivation sample. A clinical algorithm based on these factors was remarkably accurate: in the retrospective validation cohort its R² was 61.2% and median absolute error (MAE) was 5.0 mg/week. Accuracy and safety was confirmed in a prospective cohort (N=43). CYP2C9 variants and VKORC1–1639 G→A were significant dose predictors in both the derivation and validation samples. In the retrospective validation cohort, the PGx algorithm had: R²= 69.1% (p<0.05 vs. clinical algorithm), MAE= 4.7 mg/week. In conclusion, a pharmacogenetic warfarin dose-refinement algorithm based on clinical, INR, and genetic factors can explain at least 69.1% of therapeutic warfarin dose variability after about one week of therapy.

Keywords

Warfarin - VKORC1 - CYP2C9 - pharmacogenetic

• References

• 1 US Food and Drug Administration.. Coumadin (warfarin sodium) tablet and injection; Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2010.. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm201100.htm Accessed June 7, 2011.
• 2 Anderson JL, Horne BD, Stevens SM. et al. A randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.. Circulation 2007; 116: 2563-2570.
• 3 Caraco Y, Blotnick S, Muszkat M.. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation : A prospective randomized controlled study. Clin Pharmacol Ther 2008; 83: 460-470.
• 4 Epstein RS, Moyer TP, Aubert RE. et al. Warfarin genotyping reduces hospitalization rates: Results from the Medco-Mayo Warfarin Effectiveness Study (MMWES).. J Am Coll Cardiol 2010; 55: 2804-2812.
• 5 Hillman MA, Wilke RA, Caldwell MD. et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype.. Pharmacogenetics 2004; 14: 539-547.
• 6 Sconce EA, Khan TI, Wynne HA. et al. The impact of CYP2C9 and VKORC1 genetic polymorphisms and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.. Blood 2005; 106: 2329-2333.
• 7 Carlquist JF, Horne BD, Muhlestein JB. et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.. J Thromb Thrombolysis 2006; 22: 191-197.
• 8 Millican E, Lenzini PA, Milligan PE. et al. Genetic-based dosing in orthopaedic patients beginning warfarin therapy.. Blood 2007; 110: 1511-1515.
• 9 Hamberg AK, Dahl ML, Barban M. et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.. Clin Pharmacol Ther 2007; 81: 529-538.
• 10 Gage BF, Eby C, Johnson JA. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.. Clin Pharmacol Ther 2008; 84: 326-331.
• 11 Schelleman H, Chen J, Chen Z. et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.. Clin Pharmacol Ther 2008; 84: 332-339.
• 12 Lenzini PA, Grice GR, Milligan PE. et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 2008; 6: 1655-1662.
• 13 Wadelius M, Chen LY, Lindh JD. et al. The largest prospective warfarin-treated cohort supports genetic forecasting.. Blood 2009; 113: 784-792.
• 14 Li C, Schwarz UI, Ritchie MD. et al. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.. Blood 2009; 113: 3925-3930.
• 15 International Warfarin Pharmacogenetics Consortium. Klein TE, Altman RB. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data.. N Engl J Med 2009; 360: 753-764.
• 16 Lazo-Lagner A, Monkman K, Kovacs MJ.. Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram. J Thromb Haemost 2009; 7: 1276-1283.
• 17 Moreau C, Pautas E, Gouin-Thibault I. et al. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: Accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.. J Thromb Haemost 2011; 9: 711-718.
• 18 Lenzini P, Wadelius M, Kimmel S. et al. Integration of genetic, clinical, and laboratory data to refine warfarin dosing.. Clin Pharmacol Ther 2010; 87: 572-578.
• 19 Ferder N, Eby CS, Deych E. et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.. J Thromb Haemost 2009; 8: 95-100.
• 20 Limdi NA, Wiener H, Goldstein JA. et al. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.. Blood Cells Mol Dis 2009; 43: 119-128.
• 21 Pirmohamed M.. Warfarin: almost 60 years old and still causing problems.. Br J Clin Pharmacol 2006; 62: 509-511.
• 22 Budnitz DS, Pollock DA, Weidenbach KN. et al. National surveillance of emergency department visits for outpatient adverse drug events.. J Am Med Assoc 2006; 296: 1858-1866.
• 23 Wysowski DK, Nourjah P, Swartz L.. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-1419.
• 24 King CR, Porche-Sorbet RM, Gage BF. et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.. Am J Clin Pathol 2008; 129: 876-883.
• 25 Dubois D, Dubois EF.. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-871.
• 26 Linder MW, Bon Homme M, Reynolds KK. et al. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.. Clin Chem 2009; 55: 1861-1868.
• 27 Cavallari LH, Langaee TY, Momary KM. et al. Genetic and clinical predictors of warfarin dose requirements in African Americans.. Clin Pharmacol Ther 2010; 87: 459-464.
• 28 Allabi AC, Gala JL, Horsmans Y.. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 2005; 15: 779-786.
• 29 Limdi NA, Wadelius M, Cavallari L. et al. International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-3834.
• 30 Limdi NA, Beasley TM, Crowley MR. et al. VKORC1 polymorphisms, haplotypes, and haplotype groups on warfarin dose among African-Americans and European-Americans.. Pharmacogenomics 2008; 9: 1445-1458.
• 31 Fennerty A, Dolben J, Thomas P. et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J 1984; 288: 1268-1270.
• 32 Cooper MW, Hendra TJ.. Prospective evaluation of a modified Fennerty regimen for anticoagulating elderly people. Age Ageing 1998; 27: 655-656.
• 33 Pengo V, Cucchini U, Denas G. et al. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation.. Thromb Haemost 2010; 103: 442-449.
• 34 Hillman MA, Wilke RA, Yale SH. et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.. Clin Med Res 2005; 3: 137-145.
• 35 Huang SW, Chen HS, Wang XQ. et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients.. Pharmacogenet Genomics 2009; 19: 226-234.
• 36 Higashi MK, Veenstra DL, Kondo LM. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.. J Am Med Assoc 2002; 287: 1690-1698.
• 37 Schwarz UI, Ritchie MD, Bradford Y. et al. Genetic determinants of response to warfarin during initial anticoagulation.. N Engl J Med 2008; 358: 999-1008.
• 38 Lindh JD, Holm L, Dahl ML. et al. Incidence and predictors of severe bleeding during warfarin treatment.. J Thromb Thrombolysis 2008; 25: 151-159.
• 39 Limdi NA, McGwin G, Goldstein JA. et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.. Clin Pharmacol Ther 2008; 83: 312-321.
• 40 Gong IY, Tirona RG, Schwarz UI. et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.. Blood 2011; 118: 3163-3171.
• 41 Eckman MH, Rosand J, Greenberg SM. et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.. Ann Intern Med 2009; 150: 73-83.
• 42 Sorensen SV, Kansal AR, Connolly S. et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.. Thromb Haemost 2011; 105: 908-919.